Evaluation of drug safety in pediatric epileptic patients: A prospective interventional study with clinical pharmacist intervention at a tertiary care teaching hospital

Author:

Wali Shashikala C.1,Mahantashetti Niranjana S.2,Ganachari Madiwalayya Shivakantayya1,Devarinti Revanasiddappa1

Affiliation:

1. Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India

2. Department of Paediatrics, JN Medical College, Belagavi, Karnataka, India

Abstract

Abstract: CONTEXT: Epilepsy is a neurological disorder that is frequently observed among the pediatric populations, with a global prevalence of 7.5% per 1000 children. The main objectives of the therapy are to prevent or manage seizures, enhance the quality of life, and provide treatment without adverse drug reactions (ADRs). However, for children with epilepsy, the treatment goals also encompass improving learning abilities and daily living routines, in addition to eliminating the root cause, as childhood represents a hazardous phase of brain development. AIMS: The aims of this study were to evaluate, monitor, and manage ADRs for antiepileptic drugs (AEDs) in the pediatric population by clinical pharmacists’ intervention. SETTINGS AND DESIGN: A 1-year prospective interventional study was conducted at a tertiary care teaching hospital among pediatric epileptic patients. SUBJECTS AND METHODS: Patients n = 141 those who were satisfied with the abovementioned study criteria and taken their informed assent and consent of the patients before initiating the study were enrolled. STATISTICAL ANALYSIS USED: Data were analyzed using Excel-MS-Window Version-12. RESULTS: n = 141 patients were observed in this study, with the male population comprising the majority at 57%, whereas the female population accounted for 42.5%. The age group between 1 and 5 years was found to be the most prevalent. A further analysis revealed that monotherapy involving sodium valproate (23%) and levetiracetam (16%) was predominantly administered. The maximum number of ADRs was related to polytherapy, with generalized neurological and gastrointestinal tract discomfort being the most common at 31%. All observed ADRs were categorized as mild in nature and 97% were deemed preventable. CONCLUSION: Sodium valproate and levetiracetam are commonly employed AEDs as a solitary therapy, wherein the likelihood of encountering an ADR is amplified in the context of polytherapy. Timely identification and perpetual vigilance in monitoring ADRs can effectively mitigate the development of medical complications, and ultimately facilitate the attainment of predetermined therapeutic outcomes.

Publisher

Medknow

Reference21 articles.

1. Single and in combination antiepileptic drug therapy in children with epilepsy:how to use it;Oliva;AIMS Medical Science,2021

2. AS3MT Polymorphism:A Risk Factor for Epilepsy Susceptibility and Adverse Drug Reactions to Valproic Acid and Oxcarbazepine Treatment in Children From South China;Fan;Frontiers in Neuroscience,2021

3. Genetic Polymorphism of GABRG2 rs211037 is Associated with Drug Response and Adverse Drug Reactions to Valproic Acid in Chinese Southern Children with Epilepsy;Lu;Pharmacogenomics and Personalized Medicine,2021

4. Revisiting the role on antiepileptic drugs in idiopathic childhood epilepsy-an observational outcomes study in Eastern India;Begum;International Journal of Health and Clinical Research,2021

5. Concepts, Beliefs, and Traditional Treatment for Childhood Seizures in a Quilombola Community in North-eastern Brazil:Analysis by the Discourse of the Collective Speech;Beltrão;International Journal of Environmental Research and Public Health,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3